Crescent Biopharma, Inc. (CBIO) vs Evolus, Inc. (EOLS)
A side-by-side comparison of Crescent Biopharma, Inc. and Evolus, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CBIO
Crescent Biopharma, Inc.
$13.94HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
EOLS
Evolus, Inc.
$7.47HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — CBIO vs EOLS
growth of $100 · dividends reinvested · last 9yCBIO -97.8% (-34.4%/yr)EOLS -35.0% (-4.7%/yr)EOLS compounded faster over this window
Log scale — wide-divergence pair
CBIO EOLS
CBIO vs EOLS: by the numbers
- •CBIO is the larger company ($518M vs $492M market cap).
- •Both run net losses; EOLS's is the smaller (-10.85% vs -1371.51% net margin).
- •CBIO grew revenue faster over the past five years (39.89% vs 32.82% CAGR).
Metrics side by side
Valuation
| Metric | CBIO | EOLS |
|---|---|---|
| P/S ratio | 43.57 | 1.55 |
| P/B ratio | 3.25 | N/A |
Profitability
| Metric | CBIO | EOLS |
|---|---|---|
| Gross margin | 100.00% | 66.25% |
| Operating margin | -1407.52% | -7.33% |
| Net margin | -1371.51% | -10.85% |
| ROE | -99.83% | N/A |
| ROIC | -102.59% | -15.54% |
Growth (annualized)
| Metric | CBIO | EOLS |
|---|---|---|
| Revenue CAGR (5Y) | 39.89% | 32.82% |
| Total return CAGR (5Y) | -24.40% | 0.46% |
Frequently asked
- Which has grown faster, CBIO or EOLS?
- Over the past five years, CBIO grew revenue faster — CBIO at a 39.89% CAGR versus EOLS at 32.82%.
- How have CBIO and EOLS total returns compared?
- Over the past 5 years, CBIO delivered -24.40% and EOLS delivered 0.46% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Crescent Biopharma ROEEvolus ROECrescent Biopharma operating marginEvolus operating marginCrescent Biopharma revenue growthEvolus revenue growthCrescent Biopharma free cash flowEvolus free cash flow
Crescent Biopharma & Evolus appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.